Slower research progress is observed on KMO inhibitors compared to IDO/TDO inhibitors, possibly due to the complex role and regulatory mechanisms of KMO, requiring further research to understand its specific role in digestive system tumors. This evidence concerns the gene TDO2 and digestive system neoplasm.